Vedolizumab Trough Levels in Inflammatory Bowel Disease: Initial Clinical Experience

被引：0
|
作者：
Badr, Al-Bawardy [1 ]
Guilherme, Piovezani Ramos [1 ]
Loftus, Edward, Jr. [1 ]
机构：
[1] Mayo Clin, Rochester, MN USA
来源：
AMERICAN JOURNAL OF GASTROENTEROLOGY | 2018年 / 113卷
关键词：
D O I：
10.14309/00000434-201802001-00111
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P-111
引用
收藏
页码：S26 / S26
页数：1
相关论文
共 50 条
  • [11] Early vedolizumab trough levels predict mucosal healing in inflammatory bowel disease
    Yacoub, W.
    Williet, N.
    Pouillon, L.
    Di-Bernado, T.
    Bittencourt, M. De Carvalho
    Nancey, S.
    Lopez, A.
    Paul, S.
    Zallot, C.
    Roblin, X.
    Peyrin-Biroulet, L.
    [J]. JOURNAL OF CROHNS & COLITIS, 2018, 12 : S334 - S334
  • [12] Role of vedolizumab trough levels in predicting clinical response in Inflammatory Bowel Disease: a multicentre prospective study
    Falzone, M. H.
    Ribaldone, D. G.
    Saracco, G. M.
    Bertani, L.
    Ceccarelli, L.
    Costa, F.
    Bottari, A.
    Fornaroli, G.
    Cusato, J.
    D'Avolio, A.
    Palermiti, A.
    Antonucci, M.
    [J]. JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1216 - I1216
  • [13] vedolizumab trough levels at week 6 and 14 correlate with clinical remission in inflammatory bowel disease patients
    Marino, M.
    Domenis, R.
    Biribin, L.
    Cifu, A.
    Navarria, L.
    Scardino, G.
    Fabris, M.
    [J]. JOURNAL OF CROHNS & COLITIS, 2020, 14 : S492 - S492
  • [14] Do Vedolizumab trough Levels Predict the Outcome of Subsequent Therapy in Inflammatory Bowel Disease?
    Levartovsky, Asaf
    Cohen, Ido
    Abitbol, Chaya Mushka
    Yavzori, Miri
    Fudim, Ella
    Picard, Orit
    Kopylov, Uri
    Ben-Horin, Shomron
    Ungar, Bella
    [J]. BIOMEDICINES, 2023, 11 (06)
  • [15] Do vedolizumab trough levels predict response to consecutive therapy in Inflammatory Bowel Disease?
    Levartovsky, A.
    Cohen, I.
    Abitbol, C. M.
    Yavzori, M.
    Fudim, E.
    Picard, O.
    Kopylov, U.
    Ben-Horin, S.
    Ungar, B.
    [J]. JOURNAL OF CROHNS & COLITIS, 2022, 16 : I451 - I451
  • [16] Do vedolizumab trough levels predict response to consecutive therapy in Inflammatory Bowel Disease?
    Levartovsky, A.
    Cohen, I.
    Abitbol, C. M.
    Yavzori, M.
    Fudim, E.
    Picard, O.
    Kopylov, U.
    Ben-Horin, S.
    Ungar, B.
    [J]. JOURNAL OF CROHNS & COLITIS, 2022, 16 : I451 - I451
  • [17] Association of trough vedolizumab levels with clinical, biological and endoscopic outcomes during maintenance therapy in inflammatory bowel disease
    Plevris, Nikolas
    Jenkinson, Philip W.
    Chuah, Cher S.
    Lyons, Mathew
    Merchant, Lynne M.
    Pattenden, Rebecca J.
    Arnott, Ian D.
    Jones, Gareth R.
    Lees, Charlie W.
    [J]. FRONTLINE GASTROENTEROLOGY, 2020, 11 (02) : 117 - 123
  • [18] EARLY VEDOLIZUMAB TROUGH LEVELS PREDICT CLINICAL RESPONSE IN A "REAL WORLD" PROSPECTIVE COHORT OF INFLAMMATORY BOWEL DISEASE PATIENTS
    Bonthala, Nirupama
    Morganstern, Bradley
    Mengesha, Emebet
    Landers, Carol
    Mould, Diane R.
    Li, Dalin
    Vasiliauskas, Eric
    Targan, Stephan R.
    McGovern, Dermot P. B.
    Melmed, Gil
    [J]. GASTROENTEROLOGY, 2020, 158 (06) : S465 - S466
  • [19] Association between trough levels of vedolizumab and therapy outcome in a cohort of patients with inflammatory bowel disease
    O'Connell, J.
    McDonagh, P.
    Hazel, K.
    Fiona, J.
    Dunne, C.
    Farrell, R.
    Harewood, G.
    Hartery, K.
    Kelly, O.
    MacCarthy, F.
    McKiernan, S.
    Murray, F.
    O'Morain, C.
    Aoibhlinn, O.
    Kevans, D.
    [J]. JOURNAL OF CROHNS & COLITIS, 2019, 13 : S473 - S473
  • [20] Vedolizumab for the Treatment of Crohn's Disease: Experience in an Inflammatory Bowel Disease Clinical Practice
    Blum, Andrew
    Nizialek, Gregory
    Parikh, Keyur
    Dave, Maneesh
    Katz, Jeffry
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2016, 111 : S276 - S276
12345